Cephalon 2Q net income rises 5 percent – BusinessWeek
By Dr. Matthew Watson
RTT News | Cephalon 2Q net income rises 5 percent BusinessWeek Biotechnology company Cephalon Inc. said Tuesday its second-quarter net income rose 5 percent on a boost in sales of the sleep disorder drug Provigil and ... Cephalon Reports Record Sales and Earnings in Second Quarter 2010MarketWatch (press release) |
Share
Comments are closed.
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research